Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2017; 38(01): 33-43
DOI: 10.4103/0971-5851.203513
Review Article

Pediatric Osteosarcoma: An Updated Review

Shachi Jain Taran
Department of Pediatrics, Sri Aurobindo Medical College and Postgraduate Institute, Indore, Madhya Pradesh, India
,
Rakesh Taran
Department of Medical Oncology, Sri Aurobindo Medical College and Postgraduate Institute, Indore, Madhya Pradesh, India
,
Nagraj B Malipatil
Clinical Pharmacologist, Banglore, Karnataka, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

Osteosarcoma (OS), the most common type of primary malignant bone tumor, is defined by the presence of malignant mesenchymal cells producing osteoid or immature bone. The peak incidence of the most frequent type of OS, i.e., high-grade central OS, occurs in the second decade of life during the adolescent growth spurt. Most patients suffer from the pain and swelling in the involved region and, usually, seek medical attention. Diagnosis is carried out by conventional radiographs, computed tomography, and magnetic resonance image (MRI). In addition, three-phase bone scans, thallium scintigraphy, dynamic MRI, and positron emission spectroscopy are new innovative promising tools. OS can be treated with surgery, radiotherapy, and chemotherapy. There is a clear need for newer effective agents for patients with OS, especially for patients who afflicted with metastatic and recurrence tumor. Monoclonal antibodies directed against OS may prove useful as treatment, either for drug delivery or for radiopharmaceuticals.

Keywords

Bone tumor - childhood malignancy - musculoskeletal tumor - osteosarcoma - radioresistance


Publication History

Article published online:
06 July 2021

© 2017. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Link MP, Eilber F. Paediatric oncology: Osteosarcoma. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Paediatric Oncology. Philadelphia, PA: Lippincott; 1989.
  • 2 Bielack SS, Bernstein ML. Osteosarcoma. In: Cancer in Children: Clinical Management. 5th ed. New York: Oxford University Press; 2005.
  • 3 Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop 2006;30:445-51.
  • 4 Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer 2009;115:1531-43.
  • 5 Arora RS, Eden TO, Kapoor G. Epidemiology of childhood cancer in India. Indian J Cancer 2009;46:264-73.
  • 6 Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 2009;219:294-305.
  • 7 Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res 2009;152:467-78.
  • 8 Ambroszkiewicz J, Gajewska J, Klepacka T, Chelchowska M, Laskowska-Klita T, Wozniak W. Clinical utility of biochemical bone turnover markers in children and adolescents with osteosarcoma. Adv Med Sci 2010;55:266-72.
  • 9 Pandha HS, Waxman J. Tumour markers. QJM 1995;88:233-41.
  • 10 Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician 2003;68:1075-82.
  • 11 Ambroszkiewicz J, Gajewska J, Klepacka T, Chelchowska M, Laskowska-Klita T, Wozniak W. A comparison of serum concentrations of biochemical bone turnover markers in patients with osteosarcoma with good and poor prognosis. Pol Merkur Lekarski 2010;29:19-26.
  • 12 DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 2007;109:813-9.
  • 13 Kager L, Zoubek A, Dominkus M, Lang S, Bodmer N, Jundt G, et al. Osteosarcoma in very young children: Experience of the Cooperative Osteosarcoma Study Group. Cancer 2010;116:5316-24.
  • 14 Del Mare S, Kurek KC, Stein GS, Lian JB, Aqeilan RI. Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma. Am J Cancer Res 2011;1:585-94.
  • 15 Markiewicz K, Zeman K, Kozar A, Golebiowska-Wawrzyniak M. Evaluation of selected cytokines in children and adolescents with osteosarcoma at diagnosis – Preliminary report. Med Wieku Rozwoj 2011;15:25-31.
  • 16 Mikulic D, Ilic I, Cepulic M, Orlic D, Giljevic JS, Fattorini I, et al. Tumor angiogenesis and outcome in osteosarcoma. Pediatr Hematol Oncol 2004;21:611-9.
  • 17 Roulston JE, Leonard RC. Serological Tumour Markers: An Introduction. Edinburgh, Scotland: Churchill Livingstone; 1993.
  • 18 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
  • 19 Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1750-7.
  • 20 Folkman J. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
  • 21 Saab R, Rao BN, Rodriguez-Galindo C, Billups CA, Fortenberry TN, Daw NC. Osteosarcoma of the pelvis in children and young adults: The St. Jude Children's Research Hospital experience. Cancer 2005;103:1468-74.
  • 22 Aziz K. Tumour markers: Current status and future applications. Scand J Clin Lab Invest Suppl 1995;221:153-5.
  • 23 Barak V, Goike H, Panaretakis KW, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem 2004;37:529-40.
  • 24 Savitskaya YA, Rico G, Linares L, Mendez T, Martinez E, Estrada E, et al. Circulating biomarker-IgM complexes in the serum of paediatric patients with osteosarcoma and Ewing's tumor. Ann Rheum Dis 2011;70 Suppl 3:189.
  • 25 Guillou L, Aurias A. Soft tissue sarcomas with complex genomic profiles. Virchows Arch 2010;456:201-17.
  • 26 Kurt AM, Unni KK, McLeod RA, Pritchard DJ. Low-grade intraosseous osteosarcoma. Cancer 1990;65:1418-28.
  • 27 Zhu L, McManus MM, Hughes DP. Understanding the biology of bone sarcoma from early initiating events through late events in metastasis and disease progression. Front Oncol 2013;3:230.
  • 28 Dahlin DC, Unni KK, editors. Osteosarcoma. In: Bone Tumors: General Aspects and Data on 8542 Cases. Springfield, IL: Charles C. Thomas; 1986. p. 269-307.
  • 29 Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin North Am 1997;44:973-89.
  • 30 Kaste SC, Pratt CB, Cain AM, Jones-Wallace DJ, Rao BN. Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: Imaging features. Cancer 1999;86:1602-8.
  • 31 Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6.
  • 32 Ritter J, Bielack SS. Osteosarcoma. Ann Oncol 2010;21 Suppl 7:vii320-5.
  • 33 Sharma DN, Rastogi S, Bakhshi S, Rath GK, Julka PK, Laviraj MA, et al. Role of extracorporeal irradiation in malignant bone tumors. Indian J Cancer 2013;50:306-9.
  • 34 Hong AM, Millington S, Ahern V, McCowage G, Boyle R, Tattersall M, et al. Limb preservation surgery with extracorporeal irradiation in the management of malignant bone tumor: The oncological outcomes of 101 patients. Ann Oncol 2013;24:2676-80.
  • 35 Fritz J, Fishman EK, Corl F, Carrino JA, Weber KL, Fayad LM. Imaging of limb salvage surgery. AJR Am J Roentgenol 2012;198:647-60.
  • 36 Yasin NF, Ajit Singh V, Saad M, Omar E. Which is the best method of sterilization for recycled bone autograft in limb salvage surgery: A radiological, biomechanical and histopathological study in rabbit. BMC Cancer 2015;15:289.
  • 37 Weisstein JS, Goldsby RE, O'Donnell RJ. Oncologic approaches to pediatric limb preservation. J Am Acad Orthop Surg 2005;13:544-54.
  • 38 Friedman MA, Carter SK. The therapy of osteogenic sarcoma: Current status and thoughts for the future. J Surg Oncol 1972;4:482-510.
  • 39 Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-6.
  • 40 Baum ES, Gaynon P, Greenberg L, Krivit W, Hammond D. Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report. Cancer Treat Rep 1981;65:815-22.
  • 41 Pratt CB, Shanks EC. Doxorubicin in treatment of malignant solid tumors in children. Am J Dis Child 1974;127:534-6.
  • 42 Jaffe N, Frei E 3rd, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 1974;291:994-7.
  • 43 Ozaki T, Flege S, Kevric M, Lindner N, Maas R, Delling G, et al. Osteosarcoma of the pelvis: Experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 2003;21:334-41.
  • 44 Pratt CB, Rivera G, Shanks E, Kumar AP, Green AA, George S. Combination chemotherapy for osteosarcoma. Cancer Treat Rep 1978;62:251-7.
  • 45 Lange B, Levine AS. Is it ethical not to conduct a prospectively controlled trial of adjuvant chemotherapy in osteosarcoma? Cancer Treat Rep 1982;66:1699-704.
  • 46 Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial. J Clin Oncol 1987;5:21-6.
  • 47 Link MP. The multi-institutional osteosarcoma study: An update. Cancer Treat Res 1993;62:261-7.
  • 48 Rosen G, Murphy ML, Huvos AG, Gutierrez M, Marcove RC. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 1976;37:1-11.
  • 49 Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 2003;21:1574-80.
  • 50 Huvos AG. Bone Tumors: Diagnosis, Treatment, and Prognosis. 2nd ed. London, UK: W.B. Saunders; 1991.
  • 51 Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993;72:3227-38.
  • 52 Lewis IJ, Nooij M, European Osteosarcoma Intergroup. Chemotherapy at standard or increased dose intensity in patients with operable osteosarcoma of the extremity: A randomised controlled trial conducted by the European Osteo Sarcoma Intergroup (ISRCTN 86294690). Proc Am Soc Clin Oncol 2003;22:816.
  • 53 Jaffe N, Robertson R, Ayala A, Wallace S, Chuang V, Anzai T, et al. Comparison of intra-arterial cis-diamminedichloroplatinum II with high-dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol 1985;3:1101-4.
  • 54 Pratt CB, Horowitz ME, Meyer WH, Etcubanas E, Thompson EI, Douglass EC, et al. Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep 1987;71:131-5.
  • 55 Kleinerman ES, Meyers PA, Raymond AK, Gano JB, Jia SF, Jaffe N. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: Tolerability, toxicity, and immune stimulation. J Immunother Emphasis Tumor Immunol 1995;17:181-93.
  • 56 Bramwell VH, Burgers M, Sneath R, Souhami R, van Oosterom AT, Voûte PA, et al. Acomparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: The first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992;10:1579-91.
  • 57 Strander H, Einhorn S. Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture. Int J Cancer 1977;19:468-73.
  • 58 Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, et al. Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003;21:2011-8.
  • 59 Hayes FA, Green AA, Senzer N, Pratt CB. Tetany: A complication of cis-dichlorodiammineplatinum (II) therapy. Cancer Treat Rep 1979;63:547-8.
  • 60 Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, et al. Twenty years of follow-up of survivors of childhood osteosarcoma: a report from the Childhood Cancer Survivor Study. Cancer. 2011;117:625-34.
  • 61 Tarkkanen M, Karhu R, Kallioniemi A, Elomaa I, Kivioja AH, Nevalainen J, et al. Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization. Cancer Res 1995;55:1334-8.
  • 62 Schulte M, Brecht-Krauss D, Werner M, Hartwig E, Sarkar MR, Keppler P, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999;40:1637-43.
  • 63 Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: An update. Pharmacotherapy 2012;32:1095-111.
  • 64 Bid HK, Houghton PJ. Targeting angiogenesis in childhood sarcomas. Sarcoma 2011;601514. [Doi: 10.1155/2011/601514].
  • 65 Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 2008;19:807-13.
  • 66 Kim A, Balis FM, Widemann BC. Sorafenib and sunitinib. Oncologist 2009;14:800-5.
  • 67 Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: Novel targeted therapies for renal cell cancer. Pharmacotherapy 2007;27:1125-44.
  • 68 Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R, et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;51:42-8.